Authors' objectives: The Belgian authorities have requested the support of KCE in completing an update of the 2009 report18 and more specifically, to offer recommendations regarding the indications in which Ig are most effective, as well as approximations to the required quantity of Ig needed to respond to patient needs in those indications.

Authors' results and conclusions: The area of Ig appears to be expanding in a context of limited supply. Evidence appears to show that this therapy offers clinical benefits in a number of (often rare) indications. However, given the rarity of these diseases, the evidence and in particular the number and size of RCTs appears to be limited and presents methodological limitations worth considering. Countries facing similar challenges (have or) are putting in place frequently updated data registrations systems which allow a continuous evaluation of this complicated and rapidly evolving area. Efforts are currently being placed on the development of international registries (e.g. the European PID registry), which could help future research and evidence generation on larger patient pools. Important questions remain regarding usage in Belgium, which will be the subject of a second KCE report on this topic, to be published next year.

Project Status: Completed

Year Published: 2019

URL for published report: https://doi.org/10.57598/R327C

URL for additional information: https://kce.fgov.be/en/polyvalent-immunoglobulins-%E2%80%93-part-1-a-rapid-review

English language abstract: An English language summary is available

Publication Type: Rapid Review

Country: Belgium

DOI: 10.57598/R327C

Organisation Name: Belgian Health Care Knowledge Centre

Contact Address: Administrative Centre Botanique, Doorbuilding (10th floor), Boulevard du Jardin Botanique 55, B-1000 Brussels, Belgium tel: +32 2 287 33 88 fax: +32 2 287 33 85

Contact Name: info@kce.fgov.be

Contact Email: info@kce.fgov.be

Copyright: Belgian Health Care Knowledge Centre (KCE)